Hosted on MSN2mon
First patient dosed in Phase Ib Pompe disease trialAro Biotherapeutics has dosed the first patient in a Phase Ib trial of ABX1100, a novel treatment for late-onset Pompe disease (LOPD), a rare inherited disorder that causes progressive muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback